Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [911]

Prophylactic tocilizumab prior to infusion of anti-CD19 CAR-T ce may reduce...

Dr Wiebke Rösler - University Hospital Zurich, Zurich, Switzerland

Prophylactic tocilizumab prior to infusion of anti-CD19 CAR-T ce may reduce toxicity in older lymphoma patients ( Dr Wiebke Rösler - University Hospital Zurich, Zurich, Switzerland )

Optimising immunoglobulin dosing can enhance patient outcomes in multiple...

Dr Elizabeth O'Donnell - Dana-Farber Cancer Institute, Boston, USA

Optimising immunoglobulin dosing can enhance patient outcomes in multiple myeloma ( Dr Elizabeth O'Donnell - Dana-Farber Cancer Institute, Boston, USA )

High-fibre dietary intervention in precursor plasma cell disorders improves...

Dr Urvi Shah - Memorial Sloan Kettering Cancer Center, New York, USA

High-fibre dietary intervention in precursor plasma cell disorders improves biomarkers of disease, may delay progression to myeloma ( Dr Urvi Shah - Memorial Sloan Kettering Cancer Center, New York, USA )

Lack of benefit of auto-HCT in MCL patients in first complete remission with...

Dr Robert Dean - Cleveland Clinic Taussig Cancer Center, Cleveland, USA

Lack of benefit of auto-HCT in MCL patients in first complete remission with undetectable MRD ( Dr Robert Dean - Cleveland Clinic Taussig Cancer Center, Cleveland, USA )

KRdc as induction therapy shows improved OS for NDMM patients

Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK

KRdc as induction therapy shows improved OS for NDMM patients ( Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK )

Post-chemo olaparib continues to improve efficacy in gBRCApv and high-risk...

Dr Judy Garber - Dana-Farber Cancer Institute, Boston, USA

Post-chemo olaparib continues to improve efficacy in gBRCApv and high-risk, HER2-negative primary breast cancer ( Dr Judy Garber - Dana-Farber Cancer Institute, Boston, USA )

Teclistamab-lenalidomide and teclistamab alone can be safely administered as...

Dr Elena Zamagni - University of Bologna, Bologna, Italy

Teclistamab-lenalidomide and teclistamab alone can be safely administered as maintenance therapy following ASCT in NDMM ( Dr Elena Zamagni - University of Bologna, Bologna, Italy )

Mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus...

Dr Adam Olszewski - Brown University, Providence, USA

Mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus rituximab plus polatuzumab vedotin in RR LBCL ( Dr Adam Olszewski - Brown University, Providence, USA )

Acalabrutinib plus venetoclax with or without obinutuzumab versus...

Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA

Acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of CLL ( Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA )

Primary IVIG supplementation reduces the risk of high-grade infections in...

Dr Heloise Cheruvalath - Medical College of Wisconsin, Milwaukee, USA

Primary IVIG supplementation reduces the risk of high-grade infections in patients receiving teclistamab therapy for MM ( Dr Heloise Cheruvalath - Medical College of Wisconsin, Milwaukee, USA )

Glofitamab with rituximab, ifosfamide, carboplatin and etoposide shows...

Dr Paolo Caimi - Cleveland Clinic, Cleveland, USA

Glofitamab with rituximab, ifosfamide, carboplatin and etoposide shows favourable efficacy in RR diffuse large B-cell lymphoma ( Dr Paolo Caimi - Cleveland Clinic, Cleveland, USA )

Pembrolizumab after chemo demonstrates promising activity in low-risk cHL

Prof Christine Mauz-Koerholz - Justus Liebig University, Giessen, Germany

Pembrolizumab after chemo demonstrates promising activity in low-risk cHL ( Prof Christine Mauz-Koerholz - Justus Liebig University, Giessen, Germany )

More from ecancer